Answers are grounded in this paper and cite their sources.
Adjuvants are essential for effective vaccine formulation, but currently only a few adjuvants with limited efficacies and application scopes are available. To address this issue, we explored covalent conjugates of monophosphoryl lipid A (MPLA) and 2,4-dinitrophenylamine (DNPA) as a new type of adjuvant. Immunological studies in mice prove that MPLA-DNPA conjugates can help a model vaccine induce robust IgG antibody and adaptive immune responses against carbohydrate and protein antigens and are much more potent adjuvants than alumthe positive controland the MPLA + DNPA mixture. Detailed profiling and comparison of the cytokines/chemokines elicited by various adjuvants suggest that the MPLA-DNPA conjugates can activate macrophages, monocytes, dendritic, T, T helper, and other immune cells to promote cellular immunity against vaccines. The results suggest a synergistic effect of covalently linked MPLA and DNPA, which act via interacting with the Toll-like receptor and recruiting endogenous anti-DNPA antibodies, respectively. Moreover, the linker between MPLA and DNPA shows a major impact on this synergistic effect, especially for the carbohydrate antigen. Eventually, the MPLA-DNPA conjugate with a longer linker containing a triazole moiety is identified as a promising adjuvant for both carbohydrate and protein vaccines worthy of further research and development.
No takes yet. Share an insight, caveat, or question.
Guo et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: